Alaunos Therapeutics Inc (TCRT) - Total Assets
Based on the latest financial reports, Alaunos Therapeutics Inc (TCRT) holds total assets worth $1.52 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Alaunos Therapeutics Inc - Total Assets Trend (2001–2025)
This chart illustrates how Alaunos Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see Alaunos Therapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
Alaunos Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Alaunos Therapeutics Inc's total assets of $1.52 Million consist of 67.0% current assets and 33.0% non-current assets. Review Alaunos Therapeutics Inc debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 46.7% |
| Accounts Receivable | $3.00K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2001–2025)
This chart illustrates how Alaunos Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Alaunos Therapeutics Inc stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alaunos Therapeutics Inc's current assets represent 67.0% of total assets in 2025, an increase from 31.8% in 2001.
- Cash Position: Cash and equivalents constituted 46.7% of total assets in 2025, up from 15.6% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 33.0% in 2001.
- Asset Diversification: The largest asset category is accounts receivable at 0.1% of total assets.
Alaunos Therapeutics Inc Competitors by Total Assets
Key competitors of Alaunos Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Vaxcyte Inc
NASDAQ:PCVX
|
USA | $3.14 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $1.11 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.16 Billion |
Alaunos Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.77 | 3.48 | 3.43 |
| Quick Ratio | 0.77 | 3.48 | 3.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-198.00K | $2.66 Million | $68.38 Million |
Alaunos Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Alaunos Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.35 |
| Latest Market Cap to Assets Ratio | 1.10 |
| Asset Growth Rate (YoY) | 7.7% |
| Total Assets | $2.97 Million |
| Market Capitalization | $3.25 Million USD |
Valuation Analysis
Above Book Valuation: The market values Alaunos Therapeutics Inc's assets above their book value (1.10x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Alaunos Therapeutics Inc's assets grew by 7.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Alaunos Therapeutics Inc (2001–2025)
The table below shows the annual total assets of Alaunos Therapeutics Inc from 2001 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $2.97 Million | +7.66% |
| 2024-12-31 | $2.75 Million | -66.66% |
| 2023-12-31 | $8.26 Million | -87.28% |
| 2022-12-31 | $64.94 Million | -31.55% |
| 2021-12-31 | $94.86 Million | -35.18% |
| 2020-12-31 | $146.34 Million | +34.12% |
| 2019-12-31 | $109.11 Million | +14.80% |
| 2018-12-31 | $95.05 Million | -9.99% |
| 2017-12-31 | $105.61 Million | -0.70% |
| 2016-12-31 | $106.35 Million | -30.82% |
| 2015-12-31 | $153.72 Million | +239.82% |
| 2014-12-31 | $45.24 Million | -36.96% |
| 2013-12-31 | $71.75 Million | -13.97% |
| 2012-12-31 | $83.40 Million | -22.85% |
| 2011-12-31 | $108.11 Million | +75.73% |
| 2010-12-31 | $61.52 Million | +23.69% |
| 2009-12-31 | $49.74 Million | +295.58% |
| 2008-12-31 | $12.57 Million | -65.77% |
| 2007-12-31 | $36.73 Million | +24.45% |
| 2006-12-31 | $29.51 Million | +210.91% |
| 2005-12-31 | $9.49 Million | +45201323.81% |
| 2004-12-31 | $21.00 | -36.36% |
| 2003-12-31 | $33.00 | -93.41% |
| 2002-12-31 | $501.00 | -82.63% |
| 2001-12-31 | $2.88K | -- |
About Alaunos Therapeutics Inc
Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Th… Read more